![Stuart Paynter](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Stuart Paynter
Director of Finance/CFO at
CERES POWER HOLDINGS PLC
Net worth: 562 752 $ as of 2026-05-30
Profile
Stuart Paynter currently works at Oxxon Therapeutics Ltd., as Director from 2017, Oxford Biomedica (UK) Ltd., as Secretary & Director, Ceres Power Holdings plc, as Chief Financial Officer & Director from 2024, and The Institute of Chartered Accountants in England & Wales, as Member.
Mr. Paynter also formerly worked at STERIS Ltd., as Finance Director-European Region from 2001 to 2007, Shire Pharmaceuticals Ltd., as Senior Director-Finance Business from 2007 to 2016, Oxford Biomedica Plc, as Chief Financial Officer & Director from 2017 to 2024, and De La Rue Plc, as Head-Finance Business Partnering from 2016 to 2021.
Mr. Paynter received his undergraduate degree from Imperial College London.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-06-11 | 49,436 ( 0.03% ) | 562 752 $ | 2026-05-30 |
Stuart Paynter active positions
| Companies | Position | Start |
|---|---|---|
| CERES POWER HOLDINGS PLC | Director of Finance/CFO | 2024-09-30 |
Institute of Chartered Accountants in England & Wales
 Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services Offers accountancy qualifications and world class business resources | Corporate Officer/Principal | - |
Oxford Biomedica (UK) Ltd.
 Oxford Biomedica (UK) Ltd. BiotechnologyHealth Technology Develops novel gene therapy products and treatment for cystic fibrosis | Director/Board Member | - |
Oxxon Therapeutics Ltd.
 Oxxon Therapeutics Ltd. BiotechnologyHealth Technology Operates as a biotechnology company | Director/Board Member | 2017-08-28 |
Former positions of Stuart Paynter
| Companies | Position | End |
|---|---|---|
| OXFORD BIOMEDICA PLC | Director of Finance/CFO | 2024-09-01 |
| DE LA RUE | Corporate Officer/Principal | 2021-06-30 |
Shire Pharmaceuticals Ltd.
 Shire Pharmaceuticals Ltd. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Director of Finance/CFO | 2016-01-31 |
STERIS Ltd.
 STERIS Ltd. Medical SpecialtiesHealth Technology Manufactures surgical and other medical supplies | Corporate Officer/Principal | 2007-06-30 |
Training of Stuart Paynter
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
79
1st degree connections
9
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 9 |
|---|---|
Ceres Power Holdings plc
 Ceres Power Holdings plc Electronic Production EquipmentElectronic Technology Engages in development and commercialization of fuel cell technology | Electronic Technology |
STERIS Ltd.
STERIS Ltd. Medical SpecialtiesHealth Technology Manufactures surgical and other medical supplies | Health Technology |
De La Rue Plc
 De La Rue Plc Commercial Printing/FormsCommercial Services Designs, manufactures and delivers bank notes and provide authentication software | Commercial Services |
Oxford Biomedica Plc
 Oxford Biomedica Plc BiotechnologyHealth Technology Operates as a contract development and manufacturing organization which provides viral vectors to pharmaceutical and biotechnology clients in cell and gene therapy fields | Health Technology |
Imperial College London
 Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Institute of Chartered Accountants in England & Wales
Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services Offers accountancy qualifications and world class business resources | Commercial Services |
Shire Pharmaceuticals Ltd.
Shire Pharmaceuticals Ltd. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
Oxxon Therapeutics Ltd.
Oxxon Therapeutics Ltd. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Oxford Biomedica (UK) Ltd.
Oxford Biomedica (UK) Ltd. BiotechnologyHealth Technology Develops novel gene therapy products and treatment for cystic fibrosis | Health Technology |
- Stock Market
- Insiders
- Stuart Paynter
